The role of Facebook groups in the management and raising of awareness of antidepressant withdrawal: is social media filling the void left by health services?
Open Access
- 17 January 2021
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Psychopharmacology
Abstract
Antidepressant withdrawal is experienced by about half of people who try to reduce or come off their medication. It can be a debilitating, long lasting process. Many clinicians misdiagnose or minimise symptoms, inadvertently prolonging suffering. Most are unable to help patients safely taper off. There has been little research into the peer support communities that are playing an increasingly important role in helping people withdraw from psychiatric medications. To illustrate the growth and activities of Facebook withdrawal groups, we examined 13 such groups. All were raising awareness of, and supporting individuals tapering off, antidepressants and were followed for 13 months. A further three groups were added for the last 5 months of the study. In June 2020, the groups had a total membership of 67,125, of which, 60,261 were in private groups. The increase in membership for the 13 groups over the study period was 28.4%. One group was examined in greater detail. Group membership was 82.5% female, as were 80% of the Administrators and Moderators, all of whom are lay volunteers. Membership was international but dominated (51.2%) by the United States (US). The most common reason for seeking out this group was failed clinician-led tapers. The results are discussed in the context of research on the prevalence, duration and severity of antidepressant withdrawal. We question why so many patients seek help in peer-led Facebook groups, rather than relying on the clinicians that prescribed the medications. The withdrawal experiences of tens of thousands of people remain hidden in these groups where they receive support to taper when healthcare services should be responsible. Further research should focus on the methods of support and tapering protocols used in these groups to enable improved, more informed support by clinicians. Support from Governments and healthcare agencies is also needed, internationally, to address this issue.Keywords
This publication has 45 references indexed in Scilit:
- Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic ReviewPsychotherapy and Psychosomatics, 2015
- Facebook Enhances Antidepressant Pharmacotherapy EffectsThe Scientific World Journal, 2014
- A literature review and meta-analysis of drug company-funded mental health websitesActa Psychiatrica Scandinavica, 2013
- Selective Serotonin Reuptake Inhibitor Antidepressant Treatment Discontinuation Syndrome: A Review of the Clinical Evidence and the Possible Mechanisms InvolvedFrontiers in Pharmacology, 2013
- Patient Online Report of Selective Serotonin Reuptake Inhibitor-Induced Persistent Postwithdrawal Anxiety and Mood DisordersPsychotherapy and Psychosomatics, 2012
- The mechanisms of tolerance in antidepressant actionProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2011
- Sharing Health Data for Better Outcomes on PatientsLikeMeJournal of Medical Internet Research, 2010
- The pharmaceutical industry and the internet: Are drug company funded depression websites biased?Journal of Mental Health, 2009
- The pharmaceutical industry and the internet: Are drug company funded depression websites biased?Journal of Mental Health, 2009
- Recognising and managing antidepressant discontinuation symptomsAdvances in Psychiatric Treatment, 2007